Genzyme's Termeer loses millions at $69 per share

Genzyme CEO Henri Termeer (photo) may have a selfish reason for refusing Sanofi-Aventis' $69-per-share offer. Yes, Termeer would get a big buyout bonus--$11 million by some estimates--but that bonus plus his own stock-related gains wouldn't make up for the loss of future pay and the loss of upside on his stock options, the Wall Street Journal figures. Report

Suggested Articles

Minerva's seltorexant helped patients fall asleep more quickly and stay asleep for longer, beating placebo and Sanofi’s Ambien in a phase 2b study.

Cannabidiol might work as a powerful antibiotic against certain drug-resistant bacteria such as methicillin-resistant S. aureus.

Krystal Biotech posted data from a phase 2 study showing its topical gene therapy closed the majority of wounds in patients with a rare skin disorder.